semaglutide and estradiol Weight loss response to in postmenopausal women with without hormone therapy use Estrogenic activity of E2-conjugated GLP-1

Eligibility assessments, dosing decisions, and continuation protocols are managed within a clinical framework that prioritizes patient safety and metabolic appropriateness

By making conscious choices in your daily routine, you can create an environment that supports your weight loss goals

GLP-3RT is a synthetic 39-amino-acid peptide engineered as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)

Fat-selective weight loss would be an additional advantage, as the STEP-1 (NCT03548935) trial demonstrated that once-weekly semaglutide 2.4 mg resulted in 3.4 kg (7.5 lb) more loss in lean body mass compared to placebo

The study was a double-blind, placebo-controlled trial with participants receiving once-weekly subcutaneous doses of tirzepatide or a placebo